Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5 participants
OBSERVATIONAL
2023-12-27
2025-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
NCT01516905
PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
NCT01540513
Comparison Study Between PET/CT and Whole-Body Diffusion Weighted MRI in the Detection of Distant Malignancies
NCT06205901
A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
NCT01083719
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Central Nervous System Malignant Tumor
Subjects may receive up to two CEST MRI's tests and/or up to two FDG PET. The physician will determine which test is appropriate based on your tumor type, past treatment history and research question. Tests will be completed at initial baseline visit and at least one other MRI/PET after the initial baseline, up to a maximum of four scans. Additionally, patients undergo finger-poke blood collection prior to receiving FDG on study.
FDG Positron Emission Tomography
Imaging using an FDG radioactive tracer to look at the head.
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDG Positron Emission Tomography
Imaging using an FDG radioactive tracer to look at the head.
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provide written informed consent for the current study.
* Willing to undergo at least one MRI (and possibly more at PI discretion) with proton and/or phosphorus magnetic resonance spectroscopy analysis.
Exclusion Criteria
* Cardiac pacemaker or artificial heart valve
* Metal plate, pin, or other metallic implant
* Intrauterine device, such as Copper-7 IUD
* Insulin or other drug pump
* Non-titanium aneurysm clips
* Previous gunshot wound
* Cochlear implant or other hearing device
* Employment history as a metalworker (had metal in eye)
* Permanent (tattoo) eye-liner
* For FDG-PET specifically: Fasting blood sugar level greater than 200mg/dl
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Terry C Burns, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-03176
Identifier Type: OTHER
Identifier Source: secondary_id
22-009871
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.